ADMA vs DNLI: stock comparison and AI forecast
Adma Biologics, Inc. (ADMA) and Denali Therapeutics Inc. (DNLI) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ADMA Adma Biologics, Inc.
- Price
- $12.73 +50.3% · 6M
- Market Cap
- $2.85B
- P/E Ratio
- 19.0x
- Size
- mid-cap
- AI Forecast
DNLI Denali Therapeutics Inc.
- Market Cap
- $3.21B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- DNLI is 1.1 times larger than ADMA by market capitalization ($3.21B against $2.85B).
- ADMA turns 35.1% of its revenue into net income, against -1768.6% for DNLI.
- ADMA carries 0.67 times debt per unit of equity, against 0.36 times for DNLI.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ADMA | DNLI |
|---|---|---|
| Market Cap | $2.85B | $3.21B |
| P/E Ratio | 19.00x | – |
| P/B Ratio | 6.50x | 3.46x |
| EPS | $0.67 | $-1.82 |
| Book Value/Share | $1.96 | $5.80 |
| Revenue/Share | $2.32 | – |
| FCF/Share | $0.59 | $-2.82 |
Profitability & Margins
| Metric | ADMA | DNLI |
|---|---|---|
| ROE | 41.6% | -33.9% |
| ROA | 24.9% | -25.0% |
| ROIC | 37.9% | -45.8% |
| Gross Margin | 68.5% | – |
| Operating Margin | 46.5% | -2992.5% |
| Net Margin | 35.1% | -1768.6% |
| EBT Margin | 45.2% | -2992.5% |
| Tax Rate | 22.2% | – |
Financial Health
| Metric | ADMA | DNLI |
|---|---|---|
| Current Ratio | 6.04x | 6.21x |
| Quick Ratio | 3.25x | 5.94x |
| D/E Ratio | 0.67x | 0.36x |
| Financial Leverage | 1.67x | 1.36x |
| Interest Coverage | 21.2x | – |
| Working Capital | $481M | $496M |
Cash Flow
| Metric | ADMA | DNLI |
|---|---|---|
| Operating Cash Flow | $141M | -$444M |
| Free Cash Flow | $133M | -$450M |
| Capital Spending | -$8M | -$6M |
| OCF Growth YoY | 116.7% | – |
| FCF Growth YoY | 226.4% | – |
| FCF/Sales | 25.6% | – |
| CapEx/Sales | 1.5% | – |
Operational Efficiency
| Metric | ADMA | DNLI |
|---|---|---|
| Asset Turnover | 0.71x | – |
| Receivables Turnover | 3.1x | – |
| Inventory Turnover | 0.6x | – |
| Fixed Assets Turnover | 7.8x | – |
| Days Sales Outstanding | 119 days | – |
| Days Inventory | 594 days | – |
| Payables Period | 80 days | – |
| Cash Conversion Cycle | 634 days | – |
Income Statement
| Metric | ADMA | DNLI |
|---|---|---|
| Total Revenue | $519M | – |
| Operating Income | $241M | -$532M |
| Net Income | $182M | -$314M |
| R&D Expense | $14M | $405M |
| SG&A Expense | $104M | – |
| Cost of Goods Sold | $163M | – |
Dividend & Shareholder Information
| Metric | ADMA | DNLI |
|---|---|---|
| Shares Outstanding | 224M | 160M |
| Net Income Growth | -12.9% | – |
| EPS Growth | -17.3% | – |
ADMA vs DNLI: stock comparison and AI forecast
Which is bigger, ADMA or DNLI?
DNLI is 1.1 times larger than ADMA by market capitalization ($3.21B against $2.85B).
Which one does Intratio's AI model rank higher, ADMA or DNLI?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.